PDCD1 and small cell lung carcinoma: Several anti-PD-1 mAbs have been developed and approved for cancer therapy, including nivolumab, pembrolizumab, and atezolizumab (26); nevertheless, about 70% of patients with small cell lung cancer do not respond well to anti-PD-1 mAbs (27).